Literature DB >> 28823870

Magnetic Resonance Imaging and Molecular Characterization of a Hormone-Mediated Murine Model of Prostate Enlargement and Bladder Outlet Obstruction.

Erin M McAuley1, Devkumar Mustafi2, Brian W Simons3, Rebecca Valek2, Marta Zamora2, Erica Markiewicz2, Sophia Lamperis4, Anthony Williams4, Brian B Roman2, Chad Vezina5, Greg Karczmar2, Aytekin Oto2, Donald J Vander Griend6.   

Abstract

Urinary complications resulting from benign prostatic hyperplasia and bladder outlet obstruction continue to be a serious health problem. Novel animal model systems and imaging approaches are needed to understand the mechanisms of disease initiation, and to develop novel therapies for benign prostatic hyperplasia. Long-term administration of both estradiol and testosterone in mice can result in prostatic enlargement and recapitulate several clinical components of lower urinary tract symptoms. Herein, we use longitudinal magnetic resonance imaging and histological analyses to quantify changes in prostatic volume, urethral volume, and genitourinary vascularization over time in response to estradiol-induced prostatic enlargement. Our data demonstrate significant prostatic enlargement by 12 weeks after treatment, with no detectable immune infiltration by macrophages or T- or B-cell populations. Importantly, the percentage of cell death, as measured by terminal deoxynucleotidyl transferase dUTP nick-end labeling, was significantly decreased in the prostatic epithelium of treated animals as compared to controls. We found no significant change in prostate cell proliferation in treated mice when compared to controls. These studies highlight the utility of magnetic resonance imaging to quantify changes in prostatic and urethral volumes over time. In conjunction with histological analyses, this approach has the high potential to enable mechanistic studies of initiation and progression of clinically relevant lower urinary tract symptoms. In addition, this model is tractable for investigation and testing of therapeutic interventions to ameliorate or potentially reverse prostatic enlargement.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28823870      PMCID: PMC5762949          DOI: 10.1016/j.ajpath.2017.07.014

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Oestrogens and prostate cancer: novel concepts about an old issue.

Authors:  Alberto Briganti
Journal:  Eur Urol       Date:  2008-12-12       Impact factor: 20.096

2.  The American Urological Association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate.

Authors:  M Kojima; Y Naya; W Inoue; O Ukimura; M Watanabe; M Saitoh; H Watanabe
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

3.  The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients.

Authors:  Gyan Pareek; Maria Shevchuk; Noel A Armenakas; Ljiljana Vasovic; David A Hochberg; Jay B Basillote; John A Fracchia
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Magnetic resonance imaging of benign prostatic hyperplasia.

Authors:  Serkan Guneyli; Emily Ward; Stephen Thomas; Ambereen Nehal Yousuf; Igor Trilisky; Yahui Peng; Tatjana Antic; Aytekin Oto
Journal:  Diagn Interv Radiol       Date:  2016 May-Jun       Impact factor: 2.630

5.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

6.  Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.

Authors:  Gero Kramer; Georg E Steiner; Alessandra Handisurya; Ursula Stix; Andrea Haitel; Birgit Knerer; Alois Gessl; Chung Lee; Michael Marberger
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

Review 7.  Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging.

Authors:  G D Grossfeld; F V Coakley
Journal:  Radiol Clin North Am       Date:  2000-01       Impact factor: 2.303

8.  Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Authors:  Tristan M Nicholson; Michael A Moses; Kristen S Uchtmann; Kimberly P Keil; Dale E Bjorling; Chad M Vezina; Ronald W Wood; William A Ricke
Journal:  J Urol       Date:  2014-08-25       Impact factor: 7.450

Review 9.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice.

Authors:  Tristan M Nicholson; Emily A Ricke; Paul C Marker; Joseph M Miano; Robert D Mayer; Barry G Timms; Frederick S vom Saal; Ronald W Wood; William A Ricke
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

View more
  2 in total

1.  Spatiotemporal Proteomics Reveals the Molecular Consequences of Hormone Treatment in a Mouse Model of Lower Urinary Tract Dysfunction.

Authors:  Samuel Thomas; Ling Hao; Kellen DeLaney; Dalton McLean; Laura Steinke; Paul C Marker; Chad M Vezina; Lingjun Li; William A Ricke
Journal:  J Proteome Res       Date:  2020-03-16       Impact factor: 4.466

2.  Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study.

Authors:  Amr S El-Dakhakhny; Tarek Gharib; Ahmed Issam; Tarek M El-Karamany
Journal:  Arab J Urol       Date:  2019-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.